1 / 7

FDA Advisory Committee Pharmaceutical Sciences November 29, 2001

Individual Bioequivalence: Strengths and Weaknesses of the Current Approach: View from the Generic Pharmaceutical Association by MDS Pharma Services. Mario Tanguay, BPharm, PhD Associate Director, Pharmacokinetics. FDA Advisory Committee Pharmaceutical Sciences November 29, 2001.

max
Download Presentation

FDA Advisory Committee Pharmaceutical Sciences November 29, 2001

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Individual Bioequivalence: Strengths and Weaknessesof the Current Approach:View from theGeneric Pharmaceutical Associationby MDS Pharma Services Mario Tanguay, BPharm, PhD Associate Director, Pharmacokinetics FDA Advisory Committee Pharmaceutical Sciences November 29, 2001

  2. Individual BioequivalenceCollaborators • GPhA Science and CRO/Biopharmaceutics Committees • MDS Pharma Services • Murray P. Ducharme, PharmD, FCCP, FCP • Marika Pasternyk DiMarco, MSc, PhD • Diane Potvin, MSc

  3. Individual BioequivalenceAdvantages of IBE • Enables one to capture the advantages of giving the same formulation twice • Replicate design has no real benefit when ABE is used • IBE may be ethically advantageous • Smaller sample size needed for highly variable drugs due to the scaling component

  4. Individual BioequivalenceDisadvantages of IBE • How robust is the assessment of switchability with current IBE approach? • BE studies are primarily designed to prove bioequivalence based on Cmax and AUCs calculations • Current BE studies are not designed to allow proper determination of a Subject * Form interaction • Reason(s) for Subject * Form interaction cannot be identified properly

  5. Individual BioequivalenceDisadvantages of IBE • Enrollment of a heterogeneous population may not be helpful • BE Studies are not properly designed to evaluate • Gender differences in PK • Age differences in PK • Race differences in PK • etc...

  6. Individual BioequivalenceDisadvantages of IBE • In clinical research, conclusions based on posteriori statistical subgroup evaluations have many times been proven to be wrong when verified in properly designed prospective studies. • These lessons should apply to switchability measurement in BE studies

  7. Individual BioequivalenceConclusion • The BE of 2 formulations of a highly variable drug will be better assessed by giving a formulation more than once to the same subject • However, it is not appropriate to assume that switchability is robustly assessed with IBE • Posteriori subgroup calculations (study not designed for this) • Contrary to the lessons we have learned over the years in Clinical Pharmacology

More Related